Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)

Acknowledgements We are grateful to Mr George Davidson and Ms Monica Jeffers for their input with writing the PRIME-RT protocol and patient information sheet. This study is co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde. Funding PRIME-RT is funded by Astrazeneca and receives core funding from CRUK Clinical Trials Unit Glasgow for the purposes of trial set-up and data collection. The trial is co-sponsored by the University Of Glasgow and NHS Greater Glasgow and Clyde.Peer reviewedPublisher PD

Un siècle de socialismes en Bretagne

1905-2005 : le parti socialiste a eu cent ans. Ce centenaire a été l’occasion pour les historiens de revenir sur l’histoire tourmentée de la SFIO, des partis socialistes (PSA, PSU) et des militants socialistes des origines à nos jours, en analysant l’implantation et le développement en Bretagne de cette force politique qui s’est affirmée depuis les années 1970 avec le nouveau PS. Des études thématiques (itinéraires, militants, élus, sociologie, réseaux…) et géographiques (études départementales et régionales) ont permis de comparer le socialisme breton, en dégageant ses spécificités, avec celui d’autres régions françaises (Bourgogne, Rhône-Alpes, Marseille…) et celui de pays européens comme la Belgique. Un état des travaux et des axes de recherche actuels est présenté dans cet ouvrage ainsi que les témoignages de cinq acteurs de la renaissance et de l’essor du PS en Bretagne permettant de mesurer l’inscription dans la société bretonne de ce courant politique né dans des conditions difficiles au début du xxe siècle

Introduction to Chapters: Creativity and Critique in Online Teaching and Learning: Innovations in Online Pedagogy

This chapter introduces the contents of the book and describes what each case study contributes to knowledge in the field. It explains what we mean by the terms creativity and critique and in so doing highlights the challenging context in which online teaching and learning is taking place

Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)

Funding Information: After publication of this article, the authors reported that the Funding information section was incomplete. The following should have been added: “This work was supported by CRUK (Grant Number C61974/A2429).”Peer reviewedPublisher PD

15-deoxy-Δ12,14-PGJ2 enhances platelet production from megakaryocytes

Thrombocytopenia is a critical problem that occurs in many hematologic diseases, as well as after cancer therapy and radiation exposure. Platelet transfusion is the most commonly used therapy but has limitations of alloimmunization, availability, and expense. Thus, the development of safe, small, molecules to enhance platelet production would be advantageous for the treatment of thrombocytopenia. Herein, we report that an important lipid mediator and a peroxisome proliferator–activated receptor gamma (PPARγ) ligand called 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2), increases Meg-01 maturation and platelet production. 15d-PGJ2 also promotes platelet formation from culture-derived mouse and human megakaryocytes and accelerates platelet recovery after in vivo radiation-induced bone marrow injury. Interestingly, the platelet-enhancing effects of 15d-PGJ2 in Meg-01 cells are independent of PPARγ, but dependent on reactive oxygen species (ROS) accumulation; treatment with antioxidants such as glutathione ethyl ester (GSH-EE); or N-acetylcysteine (NAC) attenuate 15d-PGJ2–induced platelet production. Collectively, these data support the concept that megakaryocyte redox status plays an important role in platelet generation and that small electrophilic molecules may have clinical efficacy for improving platelet numbers in thrombocytopenic patients